InMed Pharmaceuticals (INM) Return on Sales (2021 - 2025)

InMed Pharmaceuticals' Return on Sales history runs 5 years deep, the most recent figure standing at 0.02% for Q4 2025.

• On a quarterly basis, Return on Sales changed 0.0% year-over-year to 0.02% in Q4 2025; TTM through Dec 2025 was 0.01%, a 1.0% increase from a year earlier, with the FY2025 full-year figure at 0.02%, changed 0.0% from the prior year.
• Return on Sales eased to 0.02% in Q4 2025 per INM's latest filing, from 0.02% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q1 2025 and bottomed at 0.16% in Q4 2021.
• The 5-year median for Return on Sales is 0.02% (2023), against an average of 0.04%.
• Across the five-year window, Return on Sales climbed 15 bps in 2023 and declined 1 bps in 2024, its largest moves.
• Year by year, Return on Sales stood at 0.16% in 2021, then surged by 72 bps to 0.04% in 2022, then soared by 73 bps to 0.01% in 2023, then sank by 94 bps to 0.02% in 2024, then slipped by 7 bps to 0.02% in 2025.
• Per Business Quant, the three latest INM Return on Sales figures stand at 0.02% (Q4 2025), 0.02% (Q3 2025), and 0.01% (Q2 2025).